{"nctId":"NCT00171314","briefTitle":"The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer","startDateStruct":{"date":"2004-03"},"conditions":["Breast Cancer"],"count":527,"armGroups":[{"label":"Upfront Zoledronic Acid","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid","Drug: Letrozole"]},{"label":"Delayed Zoledronic Acid","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid","Drug: Letrozole"]}],"interventions":[{"name":"Zoledronic acid","otherNames":["ZOL446","Zometa®"]},{"name":"Letrozole","otherNames":["Femara®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage I-IIIa breast cancer\n* Postmenopausal\n* Recent surgery for breast cancer\n\nExclusion Criteria:\n\n* Metastatic disease\n* Invasive bilateral disease\n* Clinical or radiological evidence of existing fracture in spine or hip\n\nOther protocol-defined inclusion / exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy","description":"Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \\[(BMD at Visit - BMD at Baseline) / BMD at Baseline\\] \\* 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.680","spread":"2.8451"},{"groupId":"OG001","value":"-3.314","spread":"3.9632"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Lumbar Spine (L2-L4) BMD at 2 Years, 3 Years, 4 Years and 5 Years","description":"Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \\[(BMD at Visit - BMD at Baseline) / BMD at Baseline\\] \\* 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.136","spread":"3.8182"},{"groupId":"OG001","value":"-3.924","spread":"4.7442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.777","spread":"4.8959"},{"groupId":"OG001","value":"-4.297","spread":"5.3583"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.462","spread":"5.2922"},{"groupId":"OG001","value":"-4.746","spread":"5.6588"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.013","spread":"5.4366"},{"groupId":"OG001","value":"-4.572","spread":"6.1617"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Lumbar Spine (L1-L4) BMD at Year 1, Year 2, Year 3, Year 4 and Year 5","description":"Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \\[(BMD at Visit - BMD at Baseline) / BMD at Baseline\\] \\* 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.330","spread":"2.7465"},{"groupId":"OG001","value":"-3.532","spread":"3.7830"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.994","spread":"3.6344"},{"groupId":"OG001","value":"-3.934","spread":"4.7162"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.523","spread":"4.5197"},{"groupId":"OG001","value":"-4.292","spread":"5.2317"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.051","spread":"4.9739"},{"groupId":"OG001","value":"-4.713","spread":"5.4101"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.476","spread":"5.0395"},{"groupId":"OG001","value":"-4.692","spread":"6.0242"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Hip BMD at Year 1, Year 2, Year 3, Year 4 and Year 5","description":"Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \\[(BMD at Visit - BMD at Baseline) / BMD at Baseline\\] \\* 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.637","spread":"2.4371"},{"groupId":"OG001","value":"-1.644","spread":"2.9994"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.119","spread":"2.9435"},{"groupId":"OG001","value":"-2.628","spread":"3.5659"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.991","spread":"3.4207"},{"groupId":"OG001","value":"-3.011","spread":"4.7684"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.439","spread":"3.5236"},{"groupId":"OG001","value":"-3.074","spread":"5.4515"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.788","spread":"3.8386"},{"groupId":"OG001","value":"-4.012","spread":"5.1321"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3","description":"Radiological Fracture at 36 months which was not present at baseline = (new fracture/number participant analyzed)\\*100. Evaluation of radiological fractures were based on central lab X-ray data. A subject with multiple fractures at the same time or multiple fractures with the same grade is counted only once for that treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":254},"commonTop":["Arthralgia","Hot flush","Fatigue","Back pain","Pain in extremity"]}}}